Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarin Pharmaceuticals Inc.

Division of Valeant Pharmaceuticals International/Amarin Pharmaceuticals Inc.
www.amarinpharma.com

Latest From Amarin Pharmaceuticals Inc.

Intercept’s NASH Drug Delayed By April Advisory Committee, But Firm Is Ready For Launch

Intercept announced that the US FDA has set April 22 as date for an advisory committee review of OCA in NASH, meaning March 26 action date could be pushed back as much as three months.

Drug Approval Standards Advisory Committees

When Expanded Access Also Means Off-Label Use, US FDA May Need New Policy

For now, FDA is using a case-by-case approach for reviewing and approving expanded access applications asking for off-label uses.
Cancer Review Pathway

How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice

Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends the "bully pulpit" approach to get industry's attention. A panel of former chief counsels stressed that the agency cannot continue to ignore First Amendment free speech issues.

Advertising, Marketing & Sales Legal Issues

Former US FDA Chief Counsels Offer Advice For Navigating Thorny First Amendment Conundrum

Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends bully pulpit approach to get attention of industry; panel of former chief counsels stresses that agency cannot continue to ignore First Amendment issues.
Advertising, Marketing & Sales Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Valeant Pharmaceuticals International
  • Senior Management
  • Steve Guillen, VP, Sales & Mktg.
    Michael J Winsor, VP, Fin.
    Bim Strausser, VP, Clinical Dev. & Medical Affairs
    Michael D Coffee, Pres. & COO
  • Contact Info
  • Amarin Pharmaceuticals Inc.
    Phone: (866) 426-2746
    Two Belvedere Pl., Ste. 330
    Mill Valley, CA 94941
    USA
UsernamePublicRestriction

Register